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An appropriate concentration of intracellular T3 is a critical determinant of placenta development
and function and is mainly controlled by the activity of type II deiodinase (D2). The levels of this
enzyme are finely regulated in different tissues by coordinated transcriptionalmechanisms, which
rely on dedicated promoter sequences (e.g. cAMP response element and TATA elements) that
impart inducibility and tissue specificity to Dio2 mRNA expression. Here we show that CCAAT
enhancer-binding proteins  and  (C/EBP and C/EBP) promote Dio2 expression in the tropho-
blastic cell line JEG3 through a conserved CCAAT element, which is a novel key component of the
Dio2 promoter code that confers tissue-specific expression of D2 in these cells. Increased C/EBPs
levels potently induce Dio2 transcription, whereas their ablation results in loss of Dio2mRNA. By
measuring the activity of several deletion and point mutant promoter constructs, we have iden-
tified the functional CCAAT element responsible for this effect, which is located in close proximity
to the most 5 TATA box. Notably, this newly identified sequence is highly conserved throughout
the species and binds in vivo and in vitro C/EBP, indicating the relevance of this regulatory mech-
anism. Together, our results unveil a novel mechanism of regulation of D2 expression in a tro-
phoblastic cell line, which may play a relevant role during placenta development. (Endocrinology
153: 4030–4038, 2012)
During gestation, the maintenance of appropriate in-tracellular T3 concentrations is a critical determi-
nant for proper development of some tissues, including
fetal brain and maternal placenta (1, 2). In these areas,
the intracellular T3 levels are promptly adjusted to the
cellular requirements by several mechanisms aimed at
preventing the severe consequences of gestational hy-
pothyroidism (e.g. cretinism, premature delivery, and
abortion). The intracellular conversion of T4 to T3, cat-
alyzed by type II deiodinase (D2), represents a critical
regulated mechanism of this process. D2 catalyzes the
removal of a single iodine from the outer ring of T4 in
the 5 position and is expressed in several tissues, in-
cluding brain, muscle, fat, thyroid, bone, and placenta
(3). The regulation of D2 levels and activity is a critical
step to control local T3 concentrations and has been
characterized in different tissues (3). D2 can be regu-
lated at the posttranslational level by ubiquitination
and de-ubiquitination mechanisms (4). Additionally, a
tight regulation of D2 levels in specific tissues and in
response to different stimuli is achieved by a fine-tuned
transcriptional control of theDio2 gene. The promoter
region of theDio2 gene has been carefully characterized
in different contexts. Several cis-acting elements have
been identified as responsible for the response to dif-
ferent stimuli or as determinants of tissue specificity (5).
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In humans, one of the tissues where the Dio2 gene is
specifically expressed and regulated is the placenta. In-
deed, D2 levels are elevated in the cytotrophoblast dur-
ing the first trimester of gestation (6), possibly as a con-
sequence of an increased need for T3 in this tissue at this
stage to support the endocrine function of placenta (7).
For this reason, D2 levels in early pregnancy appear to
be carefully regulated by multiple mechanisms. In our
previous work, we have characterized the promoter ar-
chitecture of the humanDio2 gene and its regulation in
the choriocarcinoma cell line JEG3, which presents
many of the biological and biochemical features asso-
ciated with early trophoblast. These cells express the -
and -subunits of the chorionic gonadotropin (CG)
gene and harbor a significant 5-deiodination activity
(8, 9). In analogy with the -subunit of CG (CG), a
paradigmatic placenta-specific gene expressed mostly
during the first trimester of gestation,Dio2 promoter is
synergistically regulated by epidermal growth factor
(EGF) and cAMP, acting through a conserved promoter
cAMP response element (CRE) and a TATA element (9,
10). Because EGF is secreted by placenta during early
gestation and cytotrophoblast expresses EGF receptor
(11), we have hypothesized that this autocrine mecha-
nism may contribute to ensure high levels of placental
D2, CG, and other critical genes during the early stage
of pregnancy.
In addition to the CRE-TATA unit, there are other im-
portant determinants of placental expression in the CG
promoter, such as CCAAT boxes, GATA elements, and
upstream regulatory elements (12).
Inparticular,CCAATboxesappear toplayamajor role
in determining the tissue specificity to CG gene. CCAAT
elements bind a bZIP family of transcription factors,
called CCAAT enhancer-binding proteins (C/EBPs) (13).
There are six members of C/EBPs (C/EBP, C/EBP,
C/EBP, C/EBP, C/EBP, andC/EBP) that play different
roles in different tissues (14). It has been demonstrated
that C/EBP and - are pivotal regulators of development
and function of placenta (15) and that their combined
ablation results in failure to develop the trophoblast (16).
Becausewe noticed several putative CCAAT elements in the
promoter region of the human Dio2 gene, the aim of this
study was to determine whether C/EBPs directly regulate
Dio2 mRNA levels and participate in the orchestrated reg-
ulation ofDio2 expression in the JEG3 placenta cell line.
Materials and Methods
Plasmids
Human reporter plasmids 1299ATGDio2Luc and 805ATG
Dio2 Luc have been previously described (8). A series of 5-
deletion promoter constructs, all lacking the region downstream
of the transcriptional start site (TSS), were constructed by PCR
using the 1.3-kb Dio2 Luc plasmid as template. The following
constructs were generated and named based on their distance to
the TSS: 590TSS, 120TSS, 101TSS, 81TSS, 61TSS, and 41TSS
Dio2 Luc.
The following primers were used: 590 TSS forward, 5-CT
GGGATGGTAC-3; 120 TSS forward, 5-CTGGCCAAAGTA
AAGCCCT-3; 101 TSS forward, 5-CCCAAGCTTCTTTCTC
AATGACGTCAAGA-3; 81 TSS forward, 5-CCCAAGCTTT
CTTTACCAAGATTAGGCTT-3; 61 TSS forward, 5-CCCA
AGCTTTCACTTCTCTATTGCAGCAA-3; 41 TSS forward,
5-CCCAAGCTTTTAGCCAGGGAATGTATAAAAG-3; and
TSS reverse, 5-GCTATCTGTCTGTGGTGCA-3.
Promoter sequences were amplified by PCR with GoTaq
Green Master Mix (Promega, Madison, WI), together with for-
ward and reverse primers that contained a 5 HindIII adaptor
sequence. PCR products were cloned into the HindIII site of
plasmid pSVOAL5, a luciferase expression vector (8).
The expression vectors pcDNA3-HA-C/EBP and pcDNA3-
Flag-C/EBPwere obtained byPCRamplification of humanpla-
cental cDNA and cloning into pcDNA3-HA and pcDNA3-Flag
vectors. The constructs have been sequenced to verify the ab-
sence of PCR-dependent errors.
Cell culture, transient and stable transfections, and
luciferase assays
JEG3 cells were cultured in MEM supplemented with 10%
fetal bovine serum and 1% L-glutamine. The day before trans-
fection, 200,000 cells per well were seeded in six-well plates and
grown overnight. For transfection, cells were incubated over-
night in Opti-MEM (Invitrogen, Carlsbad, CA) with 0.9 g lu-
ciferase reporter plasmid, 1 g of the indicated expression vec-
tors, and5l Lipofectinperwell (Invitrogen). PlasmidRSV-gal
(0.1g/well), which expresses-galactosidase under the control
of the RSV promoter, was used in all transfections to normalize
the luciferase activity. The empty expression vector pcDNA3
(Invitrogen) was used, when necessary, to maintain a total of 2
g f plasmid DNA. After transfection, cells were lysed in 0.5%
Triton X-100, 0.25 M Tris (pH 8), and luciferase activity was
measured.
To generate stably overexpressing C/EBP (JEG3) and -
(JEG3) cell lines, JEG3 cells were transfected with pcDNA3-
HA-C/EBP and pcDNA3-Flag-C/EBP plasmids (see above).
Stably transfected cells were selected by incubation with 0.8
mg/ml Geneticin (Life Technologies, Grand Island, NY), and
single clonal cells were isolated and grown. The level of expres-
sion of C/EBP or - proteins in the clonal cells was verified by
Western blot assay.
RNA isolation and semiquantitative and
quantitative RT-PCR
Total RNA was isolated with RNeasy mini Kit (QIAGEN,
Valencia, CA) according to the manufacturer’s instructions. Re-
verse transcription was performed with 1 g total RNA using
Superscript II and random hexamers (Invitrogen). Semiquanti-
tative PCR was performed as previously described (9), using
primers specific to Dio2 and -actin cDNA.
The primers used to amplify the humanDio2 cDNA were for-
ward 5-GCATGCTGACCTCAGAGGGACTGCGCTGCGTC
Endocrinology, August 2012, 153(8):4030–4038 endo.endojournals.org 4031
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/153/8/4030/2424250 by D
ip Biotecnologie C
ellulari user on 06 Septem
ber 2019
TGG-3andreverse5-AACCAGCTAATCTAGTTTTCTTTCAT
CTCTTGCTG-3. For human -actin, the following primers were
used: forward5-CTACAATGAGCTGCGTGTGG-3andreverse
5-CGGTGAGGATCTTCATGAGG-3.
Quantitative real-time PCR was performed as described pre-
viously (17) with the following primers: human Dio2, forward
5-AGCTTCCTCCTCGATGCCTAC-3 and reverse 5-CCAC
TGTTGTCACCTCCTTCTGT-3, and human GAPDH, for-
ward 5-GTATTCCCCCAGGTTTACAT-3 and reverse
5-TTCTGTCTTCCCTCACTCC-3.
mRNA stability
To determine the stability of Dio2 mRNA, cells were incu-
bated with 5 g/ml actinomycin D (Sigma Chemical Co., St.
Louis, MO) for the indicated times. RNA was extracted, and
semiquantitative RT-PCR was performed as described above.
Densitometric analysis was performed using NIH ImageJ
software.
RNA interference
RNA interference experiments were performed using the fol-
lowing small interfering RNA (siRNA) smart pools (Dharmacon,
Lafayette, CO): 100 nM human C/EBP (M006422030005), 100
nM human C/EBP (M006423030005), and 100 nM nontargeting
SMART pool (D-001206-13). siRNA transfections were per-
formed by incubating JEG3 cells with Lipofectamine 2000 (Invit-
rogen) in Opti-MEM for 6 h. After transfection, cells were grown
for another 48h.The efficacy of the knockdownwasmonitored by
C/EBP Western blot analysis and was always greater than 95%.
PCR-based mutagenesis
Plasmid 1299 ATG TATA MUT Dio2 Luc has been previ-
ously described (10). To generate pointmutations of theCCAAT
box sequence in the 1299 ATG Dio2 Luc plasmid, the
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA) was used. The primer sequences containing the mu-
tations were human Dio2 CCAATMUT, forward 5-TTTCAC
TTCTCTATGGCAGCACTTAGCCAGGG-3 and reverse
5-CCCTGGCTAAGTGCTGCCATAGAGAAGTGAAA-3.
Western Blot
To perform Western blot experiments on C/EBP and
C/EBP JEG3 stable lines, cells were lysed in sodium dodecyl
sulfate/urea buffer (17) and sonicated. Forty micrograms of cell
lysates were loaded, andWestern blot was performed following
standard techniques. Antibodies against C/EBP (SC-61) and
C/EBP (SC-150) were from Santa Cruz Biotechnology (Santa
Cruz, CA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as previ-
ously described (9). Briefly, cells were incubated with 1% form-
aldehyde for 20 min at room temperature to cross-link proteins
toDNA.After cross-linking, cellswere lysed [3%sarkosyl, 5mM
EDTA, 50 mM Tris-HCl (pH 8.1), plus protease inhibitors] and
sonicated to reduce the genomic DNA into small fragments
(400–600 bp). The lysates were precleared with protein A-aga-
rose and nonspecific antibodies for 2 h at 4 C. After preclearing,
the lysates were incubated with control IgG, C/EBP, and
C/EBPantisera (SantaCruzBiotechnology) overnight at 4C.At
the end of the incubation, the immunocomplexes were washed
extensively and eluted, the cross-linking was reversed, and the
DNA purified, precipitated, and resuspended. Eluted DNA was
analyzed with quantitative real-time PCR using primers encom-
passingDio2 or the unrelatedGAPDH gene. Quantitative ChIP
was performed as already described (9). The following primers
were used: human Dio2 CCAAT WT (primers A), forward 5-
GCCAAAGTAAAGCCCTCTTTCTC-3 and reverse 5-GCCT
TTTATACATTCCCTGGCTAA-3; humanDio2 intron (prim-
ers B), forward 5-TGATTTTCGCCCTGGTCTTT-3 and re-
verse 5-CATTCTTCTCAAGCCTGGTTGA-3; andGAPDH,
forward 5-AGAACATCATCCCTGCCTCT-3 and reverse
5-CACCTGGTGCTCAGTGTAG-3.
Recombinant proteins
C/EBP and C/EBP recombinant proteins have been gener-
atedwith TNTT7CoupledReticulocyte Lysate SystemKit (Pro-
mega), according to the manufacturer’s instructions, using
pcDNA3-HA-C/EBP and pcDNA3-Flag-C/EBP plasmids.
Electrophoretic mobility shift assay
Binding reactions mixture contained 0.6 ng 32P-labeled oli-
gonucleotide probe, 15 g recombinant proteins, 2 g poly (de-
oxyinosine-deoxycytosine), 200 mM KCl, 75 mM HEPES (pH
7.9), 5 mM EDTA, 2.5 mM dithiothreitol, and 25% glycerol in a
total volume of 25 ml. To perform supershift experiments, 2 g
of the anti-C/EBP antibody (Santa Cruz Biotechnology) were
added to the binding reaction mixture. In competition experi-
ments, 100-foldmolar excess of coldoligonucleotideswas added
to the binding reactionmixture. The following oligonucleotide
probes were used: human Dio2 CAAT WT, forward 5-TT
TCACTTCTCTATTGCAGCAATTAGCCAGGG-3 and re-
verse 5-CCCTGGCTAATTGCTGCAATAGAGAAGTGA
AA-3; and human Dio2 CAAT MUT, forward 5-TTTCAC
TTCTCTATGGCAGCACTTAGCCAGGG-3and reverse5-
CCCTGGCTAAGTGCTGCCATAGAGAAGTGAAA-3.
Reaction mixtures were incubated for 30 min at room tem-
perature, resolved on nondenaturing 4% polyacrylamide gel,
dried, and exposed to autoradiography.
Statistical analysis
The results presented in figures are representative of at least
three independent experiments with comparable results.
Statistical differences were tested using theMann-WhitneyU
test when treatment and control samples were analyzed or with
nonparametric ANOVA (Kruskal-Wallis test) when more than
two treatments were analyzed. Where significant differences
were observed (P 0.05) using ANOVA, pairwise comparisons
were carried out using Dunn’s multiple-comparisons test. All
statistical tests are indicated in the figure legends. Differences
were considered significant atP 0.05. Statistical analyses were
performed using Instat GraphPad version 3.06 statistical soft-
ware (GraphPad Inc., San Diego, CA).
Results
Dio2 gene is regulated by C/EBPs
The promoter region of the humanDio2 gene contains
potential binding sites for C/EBP proteins (Table 1), and
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the activity of these transcription factors have been linked
to the regulation of key genes during early trophoblast
development (15, 16). To determine whether C/EBPs
could also regulate transcription of Dio2 gene in a pla-
centa cell line, we first performed a luciferase assay on the
1.3-kb regionof theDio2promoter in JEG3cells. Previous
studies have shown thatC/EBPand -arepredominantly
expressed in placenta cells (15). Therefore,we focused our
studies on these two isoforms.
As shown in Fig. 1A, overexpression of both C/EBP
and C/EBP strongly induced Dio2 promoter. To verify
that C/EBPs increase the levels of endogenous Dio2
mRNA, we performed RT-PCR studies in JEG3 cells sta-
bly expressing C/EBP and C/EBP (JEG3 and JEG3;
Fig. 1B). As shown in Fig. 1B, Dio2 mRNA levels were
higher in JEG3 and JEG3 cells overexpressing the tran-
scription factors compared with control JEG3 cells trans-
fected with empty vector.
Previous studies have shown that the stability of Dio2
mRNA is differentially affected by different stimuli and
transcription factors (9). To measure the stability of the
C/EBP-induced transcript, we incubated JEG3 cells with
actinomycin D for different times. The calculated half-life
TABLE 1. Potential C/EBP sites in Dio2 promoter
C/EBP site
1 TCAAT (1002/997 ATG) (291 TSS 286 TSS)
2 GCAAT (833/828 ATG) (122 TSS 117 TSS)
3 TCAAT (803/798 ATG) (92 TSS 87 TSS)
4 ATTGCAGCAAT (760/749 ATG) (49 TSS 44 TSS)
(43 TSS 37 TSS)
5 GCAAT (503/498 ATG)
6 ACCAT (461/456 ATG)
Numbers in parentheses indicate the positions of the different sites
from the translational start site (ATG) and from the most 5’
transcriptional start site (TSS).
FIG. 1. A, Dio2 gene is induced by C/EBPs: luciferase assay of 1299 ATG Dio2 luc promoter construct in JEG3 cells. Cells were seeded in six-well
plates and transfected with 1299 ATG Dio2 Luc, RSV -gal, C/EBP, and C/EBP plasmids. At the end of the incubation, luciferase and -
galactosidase assays were performed. ANOVA test: *, C/EBP vs. control, P  0.05; **, C/EBP vs. control, P  0.001. Results represent the
average value  SD of three different experiments, each performed in triplicate. B, Endogenous expression of Dio2 mRNA in JEG3-C/EBP and
JEG3-C/EBP stable cell lines; top, Western blot (WB) with C/EBP and C/EBP antisera; bottom, RT-PCR analysis, using primers specific for Dio2
and -actin cDNA. C, Stability of C/EBP-induced transcript. C/EBP stable cell line (JEG3) cells were incubated with 5 g/ml actinomycin D for the
indicated times. At the end of the incubation, total RNA was extracted and reverse transcribed, and the cDNA was amplified with primers
complementary to Dio2 and -actin genes (top); bottom, densitometric analysis of the gel. D, Effect of siRNA-mediated knockdown of C/EBPs on
Dio2 mRNA expression; top, quantitative RT-PCR of RNA extracted from JEG3 cells transfected with control (siCtr) and C/EBP and C/EBP siRNA,
with Dio2 mRNA levels normalized to GAPDH mRNA levels; bottom, Western blot with C/EBP, C/EBP, or tubulin antisera to show the efficacy of
siRNA-mediated knockdown. ANOVA test: *, C/EBP vs. control, P  0.001; **, C/EBP vs. control, P  0.001. Results represent the average
value  SD of three different experiments, each performed in triplicate.
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for thisC/EBP-induced transcriptwas 3.5 h (Fig. 1C). Sim-
ilar data were obtained with JEG3 cells (not shown).
To understand the physiological relevance of the
C/EBPs regulation on Dio2 gene expression, we next ex-
amined the consequences of siRNA-mediated knockdown
of both transcription factors in JEG3 cells. After 48 h from
the siRNA transfection, we observed an almost complete
loss of both C/EBP and C/EBP proteins (Fig. 1D, bot-
tom). Remarkably, Dio2 mRNA levels were strongly re-
duced in both C/EBP- and C/EBP-deficient cells (Fig.
1D, top), as assessed by real-time quantitative PCR. These
data demonstrate that both transcription factors are es-
sential to basal Dio2 mRNA expression in these cells.
Mapping of the C/EBP-responsive sequence
Because the promoter region ofDio2 gene has multiple
potential CCAATboxes (Table 1 and Fig. 2), we sought to
identify the sequence involved in the response to C/EBPs.
We first tested the 5 and 3 deletion mutant constructs
depicted in Fig. 2A. All the constructs tested showed a
significant response toC/EBP, including the smaller plas-
mid, starting at nucleotide 120 relative to the TSS.
Therefore, we generated and tested a series of micro-
5-deletionmutants, starting from the 120TSS constructs.
With this approach, we isolated a 20-bp region, between
nucleotides61 and41, that was essential to confer the
response to C/EBP (Fig. 2B). Sequence analysis of this
20-nucleotide fragment revealed the presence of a C/EBP-
binding site (ATTGCAGCAAT; Fig. 3A), which differs
from a canonical consensus site (ATTGCGCAAT) only
for a single nucleotide insertion and is separated from the
most 5 Dio2 TATA box by 13 nucleotides. Sequence
alignment showed that the putative C/EBP site, the down-
stream region, and the TATA box are highly conserved
throughout the species (Fig. 3A).
To determine whether the putative site is functional, we
introduced two point mutations in the CCAAT site (see Fig.
1299 ATG EmptyLuc
TSS1 2 3 4 5 6A
*
C/EBPβ
805 ATG Luc
4 5 6
1 2 3 4
*
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3 4
*
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4
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*
*
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Empty vector
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Fold change
FIG. 2. A, Luciferase assay of Dio2-Luc promoter constructs in JEG3 cells. Cells were seeded in six-well plates and transfected with 1299 ATG, 805
ATG, 590 TSS, 120 TSS Dio2 Luc (schematic representation on the left), RSV -gal, and C/EBP plasmids. At the end of the incubation, luciferase
and -galactosidase assays were performed. *, C/EBP vs. control, P  0.05, Mann-Whitney test U test. Results represent the average value  SD
of three different experiments, each performed in triplicate. The numbered circles represent the potential Dio2 CCAAT elements. B, Luciferase
assay of Dio2-Luc promoter constructs in JEG3 cells. Cells were seeded in six-well plates and transfected with 101 TSS, 81 TSS, 61 TSS, 41 TSS
Dio2 Luc, RSV  gal and C/EBP plasmids. At the end of the incubation, luciferase and -galactosidase assays were performed. *, C/EBP vs.
control, P  0.05, Mann-Whitney test U test. Results represent the average value  SD of three different experiments, each performed in triplicate.
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3B)bysite-directedmutagenesis followedbyluciferaseassay.
As shown in Fig. 3B, mutation of the CCAAT site in the
context of the 1299ATGDio2 Luc construct resulted in the
complete loss of C/EBP response, demonstrating that
C/EBP induces Dio2 promoter exclusively through the
identified CCAAT element.
The5-flanking regionhumanDio2genehas a complex
organization and contains multiple TATA boxes and TSS
(8, 18). Therefore, we wondered whether C/EBPworks in
concertwith the nearbyTATAbox (themost 5TATAbox)
or other TATA or potential non-TATA elements. To this
end,we tested the response of the 1299Dio2 regionmutated
inthemost5TATAbox(TATAMUT).AsshowninFig.3B,
C/EBP was unable to induce transcription of the mutant
construct, thus demonstrating that the CCAAT unit is func-
tionallydependenton the integrityof themost5TATAbox.
Analysis of the binding of C/EBPs to Dio2
promoter
To determine whether C/EBPs are recruited toDio2 pro-
moter in vivo, we performed quantitative chromatin immu-
noprecipitation experiments. As shown
in Fig. 4A,when the PCRwas performed
with primers encompassing the Dio2
CCAAT promoter region (primers A,
Fig. 4A, bottom), a strong enrichment
was detected in C/EBP andC/EBP im-
munoprecipitation samples, compared
with IgG control. In contrast, no enrich-
ment was detected when using primers
amplifying an intronic region located
2000ntdownstreamfromtheTSS(prim-
ers B, Fig. 4A, bottom) or with primers
amplifying the coding region of the
GAPDH gene. Thus, these data demon-
strate thatC/EBPand - efficientlybind
Dio2 promoter in vivo.
To study whether C/EBPs bind di-
rectly to the identified responsive se-
quence, we performed EMSA (Fig. 4B).
The addition of recombinant flag-tagged
C/EBP to a radiolabeled oligonucleo-
tide containing the Dio2 C/EBP site
caused the formation of a DNA-protein
complex (see lane 2). The band was spe-
cifically supershifted upon addition of
anti-C/EBP antibodies (lane 3). The ad-
dition of 100 excess coldwild-type oli-
gonucleotide completely displaced the
complex (lane 4), whereas addition of
100 excess cold mutated oligo (same
mutation of Fig. 3B) failed to compete
with the labeled oligonucleotide (lane 5).
Taken together, these data demonstrated that C/EBPs
bind in vivo and in vitro Dio2 promoter.
Discussion
In the present work, we have demonstrated the relevance
of C/EBP transcription factors in the regulation of Dio2
gene expression in a human placenta cell line.
The time-restricted expression of several genes in spe-
cific tissues is governed by the concerted action ofmultiple
transcription factors, working in an orchestrated fashion
on specific promoter modules. One of these genes appears
to beDio2, which is expressed in selected tissues as a result
of dedicated mechanisms acting at the promoter level.
A well-known case of such regulation occurs in human
thyroid,where it has been demonstrated that humanDio2
gene is highly expressed thanks to thepresence of a thyroid
transcription factor-1 response element located in the en-
hancer region of human but notmouse gene (19). Another
FIG. 3. A, Top, sequence of the 20-nucleotide region (61 to 41) containing the CCAAT
element (underlined bold) in human Dio2 promoter; bottom, sequence alignment of this
region in various species; bold indicates C/EBP binding sites and TATA boxes. The numbers
indicate the position of the two elements, relative to the most 5 TSS in human Dio2. B,
Luciferase assay of 1299 ATG Dio2 Luc promoter constructs in JEG3 cells. Cells were seeded
in six-well plates and transfected with 1299 ATG WT Dio2 Luc, 1299 ATG CCAAT MUT Dio2
Luc, 1299 ATG TATA MUT Dio2 Luc, RSV -gal, and C/EBP plasmids. At the end of the
incubation, luciferase and -galactosidase assays were performed. *, C/EBP vs. control, P 
0.001, Mann-Whitney test U test. Results represent the average value  SD of three different
experiments, each performed in triplicate. Bottom, Wild-type and mutant sequences (the
underlined letters indicate the point mutations).
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mechanism of tissue-specific expression ofDio2 gene has
been elucidated in cardiac muscle. In cardiomyocytes,
Dio2 expression is regulated by the combined action of
two transcription factors, NKX 2.5 and GATA4, that im-
part tissue specificity to the gene through the binding to
specific promoter sequences (20).
In our previous studies, we have sought to understand
how Dio2 gene is regulated and selectively expressed in
JEG3, a cell line recapitulating several features of the early
trophoblast. We have compared Dio2 gene with a para-
digmatic example of a placenta-specific gene: the -sub-
unit of CG (CG). Interestingly, analogies between the
two genes have emerged from our studies. Both genes are
regulatedby the cAMP-proteinkinaseA signaling through
activation of the transcription factor CRE-binding pro-
tein, which specifically binds to conserved CRE sites lo-
cated in their promoter regions (8, 10, 18, 21). In both
cases, the CRE is located in proximity to a functional
TATA box, which is a critical feature needed to confer a
full response to cAMP agonists (22). In addition, both
genes are similarly regulated by EGF, which acts syner-
gistically with cAMP agonists through activation of a
composite transcription factor module, consisting of
CRE-binding protein, cJun, and cfos, which are activated
and recruited to the CRE in a single complex (9, 12).
With this work, we have added further complexity to
this model. We have demonstrated that the specific ex-
pression ofDio2 gene in trophoblastic cells is governed by
anadditional commonpromoter sequence, representedby
the CCAAT enhancer binding element, which is remark-
ably conserved throughout the species. In analogywith the
CG promoter, this functional CCAAT element is located
nearby the TATA box and needs its integrity to properly
function (23).
We have demonstrated that C/EBP and C/EBP,
which are expressed in the early trophoblast, bind in vivo
and in vitro to this CCAAT box and potently induceDio2
mRNA expression in JEG3 cells. In addition, a strong re-
FIG. 4. A, Quantitative chromatin immunoprecipitation. JEG3 cells were cross-linked with 1% formaldehyde and lysed. The lysates were sonicated
and immunoprecipitated with control IgG, C/EBP, and C/EBP antisera. At the end of the incubation, the immunocomplexes were washed
extensively and eluted, the cross-linking was reversed, and the DNA was purified, precipitated, and resuspended in Tris-EDTA buffer. Quantitative
PCR was performed using primers amplifying Dio2 CCAAT sequence (primers A), an intronic region of Dio2 gene (primers B), and the unrelated
GAPDH gene. ANOVA test: *, C/EBP vs. control, P  0.05; **, C/EBP vs. control, P  0.001. Results represent the average value  SD of three
different experiments, each performed in triplicate. hDio2, Human Dio2. B, EMSA. 32P-Labeled Dio2 CCAAT oligonucleotide probe, recombinant
flag-tagged C/EBP, anti-C/EBP antibody, 100-fold molar excess of cold wild-type (wt) and cold mutated (mut) oligonucleotides were added to
the reaction, as indicated. The free probe is indicated. The indicated retarded bands represent the complex between recombinant C/EBP and the
Dio2 CCAAT probe (DNA-protein complex) or the supershift upon addition of antisera (supershift).
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duction of Dio2 transcription is observed in JEG3 cells
upon ablation of both transcription factors ormutation of
the CCAAT box, indicating a crucial role of this mecha-
nism for the physiological maintenance of basal Dio2
mRNA levels in this placenta cell line.
The maintenance of proper levels of T3 in human pla-
centa has been suggested to be critical during the early
stage of gestation to support the proliferation and the en-
docrine functions of the expanding trophoblast (7). Be-
causeC/EBPs aremediators of the response to a number of
extracellular cues (e.g. cytokines, insulin, and thyroid hor-
mones) (14), it may be speculated that the Dio2 CCAAT
box could also be involved in the response to proliferating
and differentiating signals acting at placenta level during
the early stage of trophoblast development. One such sig-
nal could be the leukemia inhibitory factor cytokine,
whichactivatesC/EBP in somecells, suchas the adipocytes
(24), and has been found to be crucial for trophoblast
development and embryo implantation (25, 26).
Another relevant issue that stems from these data is
whether the effect of C/EBP on Dio2 gene expression is
important in other areas. In this regard, previous studies
have shown that mice lacking C/EBP display impaired
thermogenesis and decreasedT3 content in brown adipose
tissue, due to low D2 activity (27). Therefore, this obser-
vation can now be explained with a direct effect of C/EBP
onDio2 expression inbrownadipose tissue, a tissuewhere
C/EBP and D2 act as master regulators of tissue devel-
opment and heat production. In addition, it has been re-
cently shown (28) that overexpressed C/EBP and - in-
duce ratDio2 gene expression in glial cells. Although the
responsive sequence has not been finely mapped in that
report, it was shown that the C/EBP-mediated regulation
occurs in a promoter fragment mapping between nucleo-
tides 83 and 37 (relative to the TSS), which overlaps
with the region that we have identified in this study.
In conclusion, we have described a novel mechanism of
regulation of Dio2 gene in a placenta cell line, whereby
CCAAT elements are critical components of a composite
promoter code, which imparts tissue specificity to this
gene. The Dio2 promoter shares several features with
CG promoter, a critical placenta-specific gene, thus in-
dicating that these two genes are part of a common tran-
scriptional program and suggesting that this mechanism
could alsoplay a relevant role in vivoduring the early stage
of trophoblast development.
Acknowledgments
Address all correspondence and requests for reprints to: Gian-
luca Canettieri, M.D., Ph.D., Department of Molecular Medi-
cine, Viale Regina Elena 324, I-00161 Rome, Italy. E-mail:
gianluca.canettieri@uniroma1.it.
This work was supported by grants from “Sapienza” Uni-
versity of Rome (University Grants prot. 0006345).
Disclosure Summary: The authors have no conflicts of inter-
est to declare.
References
1. Porterfield SP, Hendrich CE 1993 The role of thyroid hormones in
prenatal and neonatal neurological development–current perspec-
tives. Endocr Rev 14:94–106
2. BurrowGN, Fisher DA, Larsen PR 1994Maternal and fetal thyroid
function. N Engl J Med 331:1072–1078
3. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002
Biochemistry, cellular and molecular biology, and physiological
roles of the iodothyronine selenodeiodinases. EndocrRev 23:38–89
4. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides
WS, Zeold A, Bianco AC 2008 Cellular and molecular basis of de-
iodinase-regulated thyroid hormone signalling. Endoc Rev 29:898–
938
5. Stoytcheva ZR, BerryMJ 2009 Transcriptional regulation of mam-
malian selenoprotein expression. Biochim Biophys Acta 1790:
1429–1440
6. Chan S, Kachilele S, Hobbs E, Bulmer JN, Boelaert K, McCabe CJ,
Driver PM, Bradwell AR, Kester M, Visser TJ, Franklyn JA, Kilby
MD 2003 Placental iodothyronine deiodinase expression in normal
and growth-restricted human pregnancies. J Clin EndocrinolMetab
88:4488–4495
7. Maruo T, Matsuo H, Mochizuki M 1991 Thyroid hormone as a
biological amplifier of differentiated trophoblast function in early
pregnancy. Acta Endocrinol (Copenh) 125:58–66
8. Canettieri G, Celi FS, Baccheschi G, Salvatori L, Andreoli M, Cen-
tanni M 2000 Isolation of human type 2 deiodinase gene promoter
and characterization of a functional cyclic adenosine monophos-
phate response element. Endocrinology 141:1804–1813
9. Canettieri G, Franchi A, Della Guardia M, Morantte I, Santaguida
MG,Harney JW,LarsenPR,CentanniM2008Activationof thyroid
hormone is transcriptionally regulated by epidermal growth factor
in human placenta-derived JEG-3 cells. Endocrinology 149:695–
702
10. Canettieri G, Franchi A, Sibilla R, Guzmán E, Centanni M 2004
Functional characterisation of the CRE/TATA box unit of type 2
deiodinase gene promoter in a human choriocarcinoma cell line.
J Mol Endocrinol 33:51–58
11. AmemiyaK, KurachiH, AdachiH,Morishige KI, Adachi K, Imai T,
MiyakeA1994 Involvement of epidermal growth factor (EGF)/EGF
receptor autocrine and paracrine mechanism in human trophoblast
cells: functional differentiation in vitro. J Endocrinol 143:291–301
12. Roberson MS, Ban M, Zhang T, Mulvaney JM 2000 Role of the
cyclic AMP response element binding complex and activation of
mitogen-activated protein kinases in synergistic activation of the
glycoprotein hormone alpha subunit gene by epidermal growth fac-
tor and forskolin. Mol Cell Biol 20:3331–3334
13. Osada S, YamamotoH,Nishihara T, ImagawaM 1996DNAbind-
ing specificity of the CCAAT/enhancer-binding protein transcrip-
tion factor family. J Biol Chem 271:3891–3896
14. Ramji DP, Foka P 2002 CCAAT/enhancer-binding proteins: struc-
ture, function and regulation. Biochem J 365:561–575
15. Bamberger AM, Makrigiannakis A, Schroder M, Bamberger CM,
Relakis C, Gellersen B, Milde-Langosch K, Loning T 2004 Expres-
sion pattern of the CCAAT/enhancer-binding proteins C/EBP-al-
pha, C/EBP-beta and C/EBP-delta in the human placenta. Virchows
Arch 444:149–152
Endocrinology, August 2012, 153(8):4030–4038 endo.endojournals.org 4037
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/153/8/4030/2424250 by D
ip Biotecnologie C
ellulari user on 06 Septem
ber 2019
16. Begay V, Smink J, Leuz A 2004 Essential requirement of CCAAT/
Enhancer binding proteins in embryogenesis. Mol Cell Biol 24:
9744–9751
17. Canettieri G, Coni S, Della Guardia M, Nocerino V, Antonucci L,
Di Magno L, Screaton R, Screpanti I, Giannini G, Gulino A 2009
The coactivator CRTC1 promotes cell proliferation and transfor-
mation via AP-1. Proc Natl Acad Sci U S A 106:1445–1450
18. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW,
Rudas P, Larsen PR 2000 Characterization of the 5-flanking and
5-untranslated regions of the cyclic adenosine 3,5-monophos-
phate-responsive human type 2 iodothyronine deiodinase gene. En-
docrinology 141:229–237
19. Gereben B, Salvatore D, Harney JW, Tu HM, Larsen PR 2001 The
human, but not rat, dio2 gene is stimulated by thyroid transcription
factor-1 (TTF-1). Mol Endocrinol 15:112–124
20. DenticeM,MoriscoC,VitaleM,RossiG, FenziG, SalvatoreD2003
The different cardiac expression of the type 2 iodothyronine deio-
dinase gene between human and rat is related to the differential
response of the Dio2 genes to Nkx-2.5 and GATA-4 transcription
factors. Mol Endocrinol 17:1508–1521
21. Deutsch PJ, Jameson JL, Habener JF 1987 Cyclic AMP responsive-
ness of human gonadotropin-alpha gene transcription is directed by
a repeated 18-base pair enhancer. Alpha-promoter receptivity to the
enhancer confers cell-preferential expression. J Biol Chem 262:
12169–12174
22. ConkrightMD,GuzmánE, Flechner L, SuAI,Hogenesch JB,Mont-
miny M 2003 Genome-wide analysis of CREB target genes reveals
a core promoter requirement for cAMP responsiveness. Mol Cell
11(4):1101–1108 Erratum in: Mol Cell 11:1417, 2003 May
23. Andersen B, Kennedy GC, Nilson JH 1990 A cis-acting element
located between the cAMP response elements andCCAATbox aug-
ments cell-specific expression of the glycoprotein hormone alpha
subunit gene. J Biol Chem 265:21874–21880
24. Belmonte N, Phillips BW,Massiera F, Villageois P,Wdziekonski B,
Saint-Marc P, Nichols J, Aubert J, Saeki K, Yuo A, Narumiya S,
AilhaudG,DaniC2001Activation of extracellular signal-regulated
kinases and CREB/ATF-1 mediate the expression of CCAAT/en-
hancer binding proteins beta and -delta in preadipocytes. Mol En-
docrinol 15:2037–2049
25. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Köntgen F, Ab-
bondanzo SJ 1992 Blastocyst implantation depends on maternal
expression of leukaemia inhibitory factor. Nature 359:76–79
26. Nachtigall MJ, Kliman HJ, Feinberg RF, Olive DL, Engin O, Arici
A1996The effect of leukemia inhibitory factor (LIF) on trophoblast
differentiation: a potential role in human implantation. J Clin En-
docrinol Metab 81:801–806
27. CarmonaMC, IglesiasR,ObregonMJ,DarlingtonGJ,Villarroya F,
Giralt M 2002 Mitochondrial biogenesis and thyroid status matu-
ration in brown fat require CCAAT/Enhancer-binding protein .
J Biol Chem 277:21489–21498
28. Lamirand A, Ramaugé M, Pierre M, Courtin F 2011 Bacterial li-
popolysaccharide induces type 2 deiodinase in cultured rat astro-
cytes. J Endocrinol 208:183–192
Members can search for other endocrinology professionals  
around the world in the online Member Directory. 
www.endo-society.org/directory
4038 Canettieri et al. C/EBP Regulation of Dio2 Gene in JEG3 Cells Endocrinology, August 2012, 153(8):4030–4038
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/153/8/4030/2424250 by D
ip Biotecnologie C
ellulari user on 06 Septem
ber 2019
